Biopharmaceutical
Pharmaceutical
Medical

Gilead Sciences

$66.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-0.42%) Today
-$0.06 (-0.08%) After Hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Employees
11,000
Headquarters
Foster City, California
Founded
1987
Market Cap
85.22B
Price-Earnings Ratio
14.74
Dividend Yield
3.65
Average Volume
7.09M
High Today
$67.48
Low Today
$66.45
Open Price
$67.30
Volume
1.89M
52 Week High
$79.61
52 Week Low
$60.32

Collections

Biopharmaceutical
Pharmaceutical
Medical
Biotechnology
Health
Research And Development
Therapy
Technology

News

BenzingaMay 23

Gilead And Kratos Defense: 'Fast Money Halftime Report' Picks From May 23

On CNBC's "Fast Money Halftime Report", Brenda Vingiello spoke about Gilead Sciences, Inc. (NASDAQ: GILD). She said expectations for this company are very low and valuation is also low. She thinks that the new CEO should drive growth by making strategic acquisitions over time. Jon Najarian likes Kratos Defense & Security Solutions, Inc (NASDAQ: KTOS). He noticed unusual options activity and he revealed that he has a long position in the name....

150
Yahoo FinanceMay 21

Top Stock Reports for Disney, Coca-Cola & Gilead

Tuesday, May 21, 2019 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Coca-Cola (KO) and Gilead (GILD). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>> Scroll to continue with content Ad Disney’s shares have gained +28.7% over the past year, outperforming the Zack...

70
Seeking AlphaMay 20

Gilead Sciences: Still A Good Pick Despite Risks

The company's Yescarta business should grow to $2.5 billion annually, and the company has several other potential R&D businesses.

233

Earnings

$1.44
$1.72
$1.99
$2.27
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 25, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.